Radiopharm reports positive Phase 1 imaging data for RAD301 in pancreatic cancer patients

• Radiopharm Theranostics reported positive Phase 1 imaging results for RAD301 in healthy volunteers, patients with pancreatic ductal adenocarcinoma.
• Results have already been presented, showing a favorable safety profile, supportive biodistribution, meaningful tumor uptake across evaluable patients.
• Low background signal in common metastatic sites supported clearer lesion detection, positioning RAD301 as a potential diagnostic, theranostic-enabling agent.
• Data supported continued clinical development, with plans to advance RAD301 into a Phase 2 imaging trial.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Radiopharm Theranostics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609090700PRIMZONEFULLFEED1001261743) on September 09, 2026, and is solely responsible for the information contained therein.